Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China
· Delayed Price · Currency is CNY 20.98
-1.12 (-5.07%)
Apr 29, 2026, 3:04 PM CST
Hybio Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 34.03 | -173.65 | -513.88 | -370.55 | 30.81 | Upgrade
|
| Depreciation & Amortization | 132.74 | 146.75 | 155.54 | 140.59 | 135.78 | Upgrade
|
| Other Amortization | 6.29 | 4.16 | 4.9 | 3.89 | 3.7 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.62 | -42.78 | 0.51 | -3.41 | -35.2 | Upgrade
|
| Asset Writedown & Restructuring Costs | 31.13 | 82.43 | 99.94 | 23.05 | 75.31 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.35 | -1.55 | -43.83 | 86.06 | -372.29 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 5.55 | 2.96 | 35.95 | 70.22 | Upgrade
|
| Other Operating Activities | 106.45 | 136.1 | 166.02 | 142.83 | 127.31 | Upgrade
|
| Change in Accounts Receivable | -49.51 | 26.37 | 121.2 | -60.54 | 17.56 | Upgrade
|
| Change in Inventory | -35.97 | -80.07 | 20.98 | -57.7 | 19.28 | Upgrade
|
| Change in Accounts Payable | 2.25 | 78.32 | -17.12 | 59.6 | 81 | Upgrade
|
| Change in Other Net Operating Assets | - | -16.53 | -0.03 | 16.56 | - | Upgrade
|
| Operating Cash Flow | 233.9 | 164.71 | -3.54 | 15.81 | 156.83 | Upgrade
|
| Operating Cash Flow Growth | 42.01% | - | - | -89.92% | 226.79% | Upgrade
|
| Capital Expenditures | -234.35 | -115.84 | -81.76 | -189.85 | -199 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.43 | 45.53 | 1.07 | 47.49 | 0.14 | Upgrade
|
| Cash Acquisitions | - | - | - | -0.1 | -3.92 | Upgrade
|
| Divestitures | 1.85 | - | - | -1.93 | - | Upgrade
|
| Investment in Securities | 2.11 | 0.3 | 228.37 | 195.29 | 21.2 | Upgrade
|
| Other Investing Activities | 3.29 | - | 0.03 | 0.82 | 3.19 | Upgrade
|
| Investing Cash Flow | -226.67 | -70.01 | 147.71 | 51.72 | -178.39 | Upgrade
|
| Short-Term Debt Issued | - | 190.4 | 12 | 5 | - | Upgrade
|
| Long-Term Debt Issued | 1,578 | 1,339 | 1,378 | 537.29 | 1,457 | Upgrade
|
| Total Debt Issued | 1,578 | 1,529 | 1,390 | 542.29 | 1,457 | Upgrade
|
| Short-Term Debt Repaid | - | -207.4 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -1,637 | -1,546 | -1,173 | -495.09 | -1,644 | Upgrade
|
| Total Debt Repaid | -1,637 | -1,753 | -1,173 | -495.09 | -1,644 | Upgrade
|
| Net Debt Issued (Repaid) | -59.69 | -224.15 | 216.25 | 47.2 | -187.81 | Upgrade
|
| Issuance of Common Stock | - | 2.14 | - | - | - | Upgrade
|
| Common Dividends Paid | -94.84 | -111.75 | -117.9 | -114.8 | -115.64 | Upgrade
|
| Other Financing Activities | 130.57 | -11.73 | -2.5 | -3.5 | 49.79 | Upgrade
|
| Financing Cash Flow | -23.96 | -345.48 | 95.85 | -71.11 | -253.67 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.48 | 3.38 | 0.92 | 2.07 | -1.58 | Upgrade
|
| Net Cash Flow | -15.25 | -247.4 | 240.94 | -1.51 | -276.81 | Upgrade
|
| Free Cash Flow | -0.45 | 48.87 | -85.3 | -174.04 | -42.17 | Upgrade
|
| Free Cash Flow Margin | -0.05% | 8.28% | -19.77% | -24.71% | -5.73% | Upgrade
|
| Free Cash Flow Per Share | - | 0.06 | -0.10 | -0.20 | -0.04 | Upgrade
|
| Cash Income Tax Paid | 6.3 | 7.42 | 59.68 | 41.6 | 65.12 | Upgrade
|
| Levered Free Cash Flow | -6.07 | 59.65 | -54.53 | -176.94 | -190.2 | Upgrade
|
| Unlevered Free Cash Flow | -6.07 | 126.21 | 20.76 | -112.4 | -135.25 | Upgrade
|
| Change in Working Capital | -74.77 | 7.7 | 124.3 | -42.62 | 121.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.